Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06340360 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

A Phase 2 study of Alopecia Areata, sponsored by Nektar Therapeutics.

Active
Registry status
Phase 2
Development phase
94
Enrollment target
20
Study locations

NCT06340360 is a Phase 2 study of Alopecia Areata that is active but no longer recruiting, run by Nektar Therapeutics. The registered enrollment target is 94 participants, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06340360, a Phase 2 study of Alopecia Areata, is active but no longer recruiting, sponsored by Nektar Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
94 participants
Enrollment target
20
Study locations

Study Summary

This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, an optional 16-week treatment extension period, and a 24-week follow-up period. The maximum study duration is approximately 81 weeks for all participants.

Conditions Studied

Alopecia Areata

Interventions

  • DRUG Placebo
  • DRUG Rezpegaldesleukin

Study Locations (20)

Ontario

  • Nektar Investigative Site - Markham
  • Nektar Investigative Site - Oakville
  • Nektar Investigative Site - Richmond Hill

Lower Silesian Voivodeship

  • Nektar Investigative Site - Wroclaw
  • Nektar Investigative Site - Wroclaw
  • Nektar Investigative Site - Wroclaw

Texas

  • Nektar Investigative Site - Frisco
  • Nektar Investigative Site - Pflugerville

California

  • Nektar Investigative Site - Northridge

Georgia

  • Nektar Investigative Site - Atlanta

Illinois

  • Nektar Investigative Site - Gurnee

Indiana

  • Nektar Investigative Site - Indianapolis

Michigan

  • Nektar Investigative Site - Clinton Township

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2024-04-02
Est. Completion 2026-08
Phase Phase 2

Sponsor

Nektar Therapeutics

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06340360

The ClinicalTrials.gov registry entry for NCT06340360 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (95% lower). The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06340360 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ontario, Lower Silesian Voivodeship, Texas.

Frequently Asked Questions

What is clinical trial NCT06340360 about?

NCT06340360 is a clinical study titled "A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)". This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a sc...

What is the current status of trial NCT06340360?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2024-04-02. Estimated completion is 2026-08.

What conditions does trial NCT06340360 study?

This clinical trial studies the following conditions: Alopecia Areata.

What interventions are being tested in trial NCT06340360?

The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).

Who is sponsoring clinical trial NCT06340360?

This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06340360 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alopecia Areata

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alopecia Areata

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.